Lancet Oncol: The team of Professor Guo Xiang from Sun Yat-sen University Cancer Hospital confirmed through a phase 3 trial that the third-generation platinum drug lobaplatin can effectively treat locally advanced nasopharyngeal carcinoma!

The National Comprehensive Cancer Network Guidelines recommends the use of cisplatin-based induction chemotherapy plus concurrent radiotherapy and chemotherapy to treat locally advanced nasopharyngeal carcinoma.

The third-generation platinum drug, Lobaplatin, has shown promising anti-tumor activity in a variety of malignant tumors with low toxicity .

Professor Guo Xiang, director of the Department of Nasopharyngology, Sun Yat-sen University Cancer Hospital, and his colleagues led a team to carry out an open-label, non-inferiority randomized controlled phase 3 clinical trial in 5 hospitals in China, aiming to evaluate the use of lobaplatin as a Basic induction chemotherapy + concurrent chemoradiation vs.

The trial recruited patients with nasopharyngeal carcinoma of stage III-IVB who were 18-60 years old who had not been treated before, and required Karnofsky performance status score ≥ 70 points, and good blood, liver and kidney function.

From June 7, 2013 to June 16, 2015, after evaluating 515 patients, 502 were recruited into the group: 252 were assigned to the lobaplatin group and 250 were assigned to the cisplatin group.

Prognosis of the intention-to-treat population

After a median follow-up of 75.

In the intention-to-treat population, 63 (25%) of 252 patients in the lobaplatin group and 250 patients in the cisplatin group each achieved progression-free survival events; in the protocol-treated population, there were 246 patients in the lobaplatin group 62 (25%) and 58 of the 237 patients in the cisplatin group (25%) achieved progression-free survival events.

Adverse events

The most common grade 3-4 adverse events were mucositis (lobaplatin group vs cisplatin group: 41% vs 40%), leukopenia (16% vs 23%), and neutropenia (10% vs 24 %).

In summary, the efficacy of lobaplatin-based induction chemotherapy combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma is not inferior to that of cisplatin-based treatment, and the side effects are smaller .

Xing Lv, et al.